Anti-TNC-C [3F4.1] monoclonal antibody
Invented at University of Tartu
- Datasheet
- References (1)
- Inventor Info
Info
Catalogue Number | 160461 |
Applications | ELISA IHC IF |
Antigen/Gene or Protein Targets | Tenascin-C, TNC-C |
Reactivity | Human |
Relevance |
Oncofetal fibronectin (FN-EDB) and tenascin-C C domain (TNC-C) are nearly absent in extracellular matrix of normal adult tissues but upregulated in malignant tissues. Both FN-EDB and TNC-C are developed as targets of antibody-based therapies. This series of antibodies has been validated in vitro against glioblastoma (GBM) and prostate carcinoma xenografts, and to non-malignant angiogenic neovessels induced by VEGF-overexpression. Please see our related anti-FN-EDB antibodies from University of Tartu. |
Host | Mouse |
Research Area | Cancer |